Data / Research funding / Vector-Borne Diseases
Vector-Borne Diseases: 2,009 NIH awards ($2.4B) to 383 organizations
2,009 NIH awards ($2.4B) in the NIH spending category Vector-Borne Diseases, to 383 organizations, read 2026-11-04. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 2,009 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Vaccine and Treatment Evaluation Units | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $22,981,366 | December 11, 2019 | November 30, 2026 | ROUPHAEL, NADINE GEORGES | reporter.nih.gov |
| Vaccine and Treatment Evaluation Unit at Saint Louis University | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,219,564 | December 11, 2019 | November 30, 2026 | HOFT, DANIEL F. | reporter.nih.gov |
| Vermont Biomedical Research Network-Vermont INBRE | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $19,534,463 | September 30, 2001 | June 30, 2030 | FRANCKLYN, CHRISTOPHER S | reporter.nih.gov |
| University of Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,173,751 | December 11, 2019 | November 30, 2026 | WALD, ANNA | reporter.nih.gov |
| Kaiser Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,173,633 | December 11, 2019 | November 30, 2026 | JACKSON, LISA A | reporter.nih.gov |
| Protective immunity following dengue virus natural infections and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,429,941 | July 29, 2015 | July 31, 2030 | HARRIS, EVA | reporter.nih.gov |
| Task A71: Comprehensive In Vivo Screening of Viral Pathogens of Pandemic Potential | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,745,278 | July 18, 2022 | July 17, 2025 | MORREY, JOHN | reporter.nih.gov |
| Complement Mediated Remodeling in Pulmonary Vascular Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $11,355,302 | August 1, 2020 | June 30, 2026 | STENMARK, KURT R. | reporter.nih.gov |
| Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,862,919 | March 22, 2022 | February 28, 2027 | FERNANDEZ-SESMA, ANA | reporter.nih.gov |
| University of Washington Arboviral Research Network (UWARN) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $9,499,281 | May 22, 2020 | June 5, 2025 | VAN VOORHIS, WESLEY C | reporter.nih.gov |
| COBRE: Eukaryotic Pathogens Innovation Center (EPIC) | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $9,118,734 | July 15, 2022 | May 31, 2027 | MORRIS, JAMES CULVIN | reporter.nih.gov |
| Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $8,743,439 | September 25, 2023 | June 24, 2024 | RAMSTEDT, URBAN | reporter.nih.gov |
| Task C16: Production and Development of Schistosomiasis Research Reagents | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,933,000 | February 1, 2023 | January 31, 2026 | MENTINK-KANE, MARGARET | reporter.nih.gov |
| Integrating innate and adaptive pathways in vaccine responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $7,762,589 | April 1, 2014 | March 31, 2024 | RAVETCH, JEFFREY VICTOR | reporter.nih.gov |
| Administrative Supplements for NIAID Regional Biocontainment Laboratories (RBL) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $7,369,853 | September 23, 2021 | February 28, 2025 | ALEM, FARHANG | reporter.nih.gov |
| EpiCenter for Emerging Infectious Disease Intelligence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $7,215,074 | July 13, 2020 | June 5, 2025 | JOHNSON, CHRISTINE KREUDER | reporter.nih.gov |
| Emerging Infectious Diseases Research Center - East and Central Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,734,930 | June 1, 2020 | June 5, 2025 | NJENGA, M KARIUKI | reporter.nih.gov |
| Lyme Disease: B cell epitope discovery and mechanisms of antibody protection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,722,146 | September 16, 2019 | September 15, 2024 | MANTIS, NICHOLAS J. | reporter.nih.gov |
| Emerging infections: surveillance, epidemiology and pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,690,286 | May 11, 2020 | June 5, 2025 | WANG, DAVID | reporter.nih.gov |
| West African Center for Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,658,566 | June 9, 2020 | June 5, 2025 | WEAVER, SCOTT C | reporter.nih.gov |
| B Cell Epitope Discovery and Mechanisms of Antibody Protection: Responses to Dengue 4, Powassan, Chikungunya, and Venezuelan Equine Encephalitis Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,634,396 | September 16, 2023 | September 15, 2024 | FREMONT, DAVED | reporter.nih.gov |
| Facility and Building System Upgrades Support for the Howard T. Ricketts Biocontainment Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,593,067 | September 16, 2021 | February 28, 2025 | ADAMS, ERIN JUNE | reporter.nih.gov |
| Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,498,374 | August 1, 2017 | July 31, 2027 | WARE, RUSSELL E | reporter.nih.gov |
| Regional Biocontainment Laboratory (RBL) Upgrade for Colorado State University (CSU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,493,184 | September 23, 2021 | February 28, 2025 | DOBOS, KAREN MARIE | reporter.nih.gov |
| Coordinating Research on Emerging Arboviral Threats Encoing the Neotropics (CREATE-NEO) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,472,246 | June 1, 2020 | June 5, 2025 | VASILAKIS, NIKOS | reporter.nih.gov |
| Small-molecule activators of STING-signaling as novel adjuvants for flavivirus vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,461,817 | September 30, 2019 | September 29, 2024 | NELSON, JAY | reporter.nih.gov |
| American and Asian Centers for Arboviral Research and Enhanced Surveillance (A2CARES) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,361,142 | July 20, 2020 | May 31, 2025 | HARRIS, EVA | reporter.nih.gov |
| Biologically informed design of CD8+ T cell-dependent pre-erythrocytic stage malaria vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,330,175 | February 4, 2021 | January 31, 2026 | KAPPE, STEFAN HI | reporter.nih.gov |
| Enhancing immunity to malaria in young children with effective chemoprevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,263,495 | July 1, 2025 | June 30, 2027 | JAGANNATHAN, PRASANNA | reporter.nih.gov |
| Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,933,702 | April 8, 2021 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| Computational models of naturally acquired immunity to falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,666,873 | April 1, 2020 | March 31, 2026 | GREENHOUSE, BRYAN R | reporter.nih.gov |
| Improving Neonatal health Through Rapid malaria testing in Early Pregnancy with high-sensitivity Diagnostics (INTREPiD) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,664,388 | April 1, 2022 | March 31, 2027 | TAYLOR, STEVE MYER | reporter.nih.gov |
| Task C08: Maintenance of Black Fly (Simulium Vittatum IS-7) Immature and Adult Stages | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,602,994 | July 10, 2020 | December 31, 2024 | GRAY, ELMER | reporter.nih.gov |
| Comparative effectiveness and complications of intravenous ceftriaxone compared with oral doxycycline in Lyme meningitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,573,382 | September 1, 2021 | August 31, 2027 | NIGROVIC, LISE E. | reporter.nih.gov |
| DON in Pediatric Cerebral Malaria: A Phase I / II Dose-Escalation Safety Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,567,850 | June 1, 2025 | May 31, 2027 | POSTELS, DOUGLAS | reporter.nih.gov |
| Inter-regional study of transmission, adaptation and pathogenesis of viruses with pandemic potential in Southeast Asia and West/Central Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,526,401 | July 17, 2020 | June 5, 2025 | SAKUNTABHAI, ANAVAJ | reporter.nih.gov |
| Comparative systems biology of apicomplexan cell division | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,447,470 | July 21, 2022 | June 30, 2027 | GUBBELS, MARC-JAN | reporter.nih.gov |
| Structure-Function Analysis of Mxra8 Interaction with Alphaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,414,348 | June 1, 2019 | July 31, 2029 | DIAMOND, MICHAEL S | reporter.nih.gov |
| DNA damage response and repair of a broken chromosome | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $5,083,668 | June 1, 2018 | May 31, 2028 | HABER, JAMES E | reporter.nih.gov |
| Focal mass drug administration (fMDA) to reduce Plasmodium vivax transmission, a pragmatic cluster randomized controlled trial in Peru | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,036,878 | June 1, 2025 | May 31, 2027 | HSIANG, MICHELLE SANG | reporter.nih.gov |
| Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2024 | $5,036,160 | September 1, 2022 | August 31, 2027 | CHANG, AILEEN | reporter.nih.gov |
| Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $5,018,496 | July 5, 2023 | May 31, 2028 | VOIGT, EMILY | reporter.nih.gov |
| Quanitifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,011,286 | April 1, 2020 | March 31, 2026 | VAZQUEZ PROKOPEC, GONZALO MARTIN | reporter.nih.gov |
| Evaluation of an OMV-adjuvanted Chimeritrope Vaccine against Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $4,961,891 | September 30, 2018 | September 29, 2023 | MORICI, LISA | reporter.nih.gov |
| Living in the post-Zika world: Impact of interactions between dengue and Zika viruses on diagnostics, antibody dynamics, and correlates of disease risk | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,905,886 | July 13, 2021 | April 30, 2027 | HARRIS, EVA | reporter.nih.gov |
| Large Scale T Cell Epitope Discovery:Global identification of epitopes derived from Zika (ZIKV), Chikungunya (CHIKV) viruses following natural infection and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,881,220 | September 30, 2019 | September 29, 2024 | MITCHELL, MAYA | reporter.nih.gov |
| IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) in murine and human atherosclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,866,733 | July 1, 2022 | June 30, 2027 | ERICKSON, LOREN D | reporter.nih.gov |
| Accelerating discovery of an efficacious Plasmodium vivax multivalent multi-stage vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,835,728 | December 1, 2020 | November 30, 2026 | ADAMS, JOHN H | reporter.nih.gov |
| Mechanisms of Cell Regulation and Manipulation by the Ubiquitin System | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,827,601 | June 1, 2020 | May 31, 2030 | HOCHSTRASSER, MARK W | reporter.nih.gov |
| Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,809,096 | April 15, 2020 | March 31, 2026 | DORSEY, MATTHEW G | reporter.nih.gov |
| Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,717,265 | April 1, 2021 | March 31, 2027 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Mechanisms of innate immune dysfunction in SIV/malaria co-infection in pregnancy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $4,672,308 | September 24, 2021 | July 31, 2026 | MANUZAK, JENNIFER | reporter.nih.gov |
| Heritable immunization of the white-footed mouse reservoir of Lyme disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,657,626 | September 1, 2021 | August 31, 2026 | ESVELT, KEVIN | reporter.nih.gov |
| DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,647,135 | June 29, 2020 | May 31, 2026 | ANTIA, RUSTOM NOSHIR | reporter.nih.gov |
| IgE antibodies to the mammalian oligosaccharide galactose-alpha-1, 3-galactose (alpha-gal): immunology, epidemiology and relevance to allergic and inflammatory disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,621,686 | July 1, 1984 | May 31, 2028 | PLATTS-MILLS, THOMAS A. | reporter.nih.gov |
| Development of the INI-4001 and INI-2002 adjuvants within the context of a vaccine to prevent Lyme disease. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $4,583,801 | September 30, 2018 | September 29, 2024 | EVANS, JAY | reporter.nih.gov |
| Long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzaniav | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,537,676 | April 15, 2022 | March 31, 2027 | HSIANG, MICHELLE SANG | reporter.nih.gov |
| Vaccine and Treatment Evaluation Units: Wolbachia-Infected Aedes aegypti Mosquitos in Reducing Arboviral Infection Brazil | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,402,306 | February 4, 2020 | November 30, 2027 | ROUPHAEL, NADINE | reporter.nih.gov |
| Genome-wide CRISPR-Cas9 screens in insect cells to characterize insecticidal toxins | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,239,439 | June 15, 2022 | May 31, 2027 | DONG, MIN | reporter.nih.gov |
| Structural Analysis and Inhibitor Optimization of Cryptosporidium n-myristoyltransferase for Drug Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,163,372 | November 15, 2020 | October 31, 2026 | STAKER, BART LEE | reporter.nih.gov |
| Integrating human and non-human primate data to understand the acquisition of pre-erythrocytic immunity in the face of previous malaria exposure | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,114,200 | February 10, 2022 | January 31, 2027 | WILDER, BRANDON KEITH | reporter.nih.gov |
| New chemotherapy regimens and biomarkers for Chagas disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,104,835 | August 17, 2018 | July 31, 2025 | ALMEIDA, IGOR C | reporter.nih.gov |
| Development of an oral liver-targeted prime-and-trap malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,104,491 | December 1, 2020 | November 30, 2026 | MURPHY, SEAN C | reporter.nih.gov |
| Mitochondrial DNA of Normal and Mutant Trypanosomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,069,462 | September 1, 1978 | April 30, 2029 | STUART, KENNETH D | reporter.nih.gov |
| Mosquito SAMSP1 and SAMSP2 influence the initial stage of Plasmodium infection of mice | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,052,693 | April 14, 2021 | March 31, 2027 | FIKRIG, EROL | reporter.nih.gov |
| Molecular elucidation of the Francisella tularensis virulence mechanism | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,049,782 | May 21, 2021 | April 30, 2027 | SCHUMACHER, MARIA | reporter.nih.gov |
| Innovations in Functional B Cell Epitope Discovery for Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $4,031,164 | September 16, 2024 | September 15, 2026 | MANTIS, NICHOLAS | reporter.nih.gov |
| Defining functional humoral correlates of immunity to guide vaccine design | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,023,233 | November 24, 2020 | October 31, 2025 | BATISTA, FACUNDO DAMIAN | reporter.nih.gov |
| World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,949,988 | February 1, 2016 | March 24, 2025 | WEAVER, SCOTT C | reporter.nih.gov |
| A systems immunology approach to evaluate malaria vaccine performance in endemic regions of Kenya | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,921,000 | February 1, 2022 | January 31, 2027 | MOORMANN, ANN M | reporter.nih.gov |
| Next generation mosquito control through technology-driven trap development and artificial intelligence guided detection of mosquito breeding habitats | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,914,766 | September 17, 2021 | August 31, 2026 | NOLAN, MELISSA SUZANNE | reporter.nih.gov |
| Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,856,328 | September 1, 2019 | August 31, 2029 | LIN, GANG | reporter.nih.gov |
| Optimization of novel phenotypic screening hits for treatment of Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,843,960 | April 1, 2021 | March 31, 2027 | PHILLIPS, MARGARET A. | reporter.nih.gov |
| Task B24: Production of Well Characterized Challenge Material (WCCM) of High Priority Viral Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,793,148 | February 29, 2024 | January 24, 2026 | TAMHANKAR, MANASI | reporter.nih.gov |
| LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,787,436 | July 1, 2021 | June 30, 2027 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Targeting the Genus Leishmania with Small Molecules | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,752,432 | March 24, 2021 | February 28, 2026 | SCHAUS, SCOTT EDWARD | reporter.nih.gov |
| Skin microbiome contributions to the pathogenesis of cutaneous leishmaniasis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,738,057 | March 4, 2019 | April 30, 2029 | SCOTT, PHILLIP | reporter.nih.gov |
| Validating the Flavivirus Envelope Protein as an Antiviral Target | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,735,490 | March 1, 2020 | February 28, 2026 | YANG, PRISCILLA LI-NING | reporter.nih.gov |
| Lead Optimization of DHODH Inhibitors for Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,721,559 | January 1, 2013 | June 30, 2028 | PHILLIPS, MARGARET A. | reporter.nih.gov |
| Enteric Pathogen Force of Infection among Children using Serology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,719,600 | July 1, 2021 | June 30, 2027 | ARNOLD, BENJAMIN F | reporter.nih.gov |
| A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,713,909 | August 21, 2019 | July 31, 2025 | KIRKPATRICK, BETH DIANE | reporter.nih.gov |
| Structure-based design of broad flavivirus immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,710,975 | September 24, 2021 | August 31, 2026 | LAI, JONATHAN R. | reporter.nih.gov |
| Functional B-cell Epitope Discovery for Arthropod-Borne Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,708,329 | September 16, 2024 | September 15, 2027 | reporter.nih.gov | |
| Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,704,381 | March 19, 2021 | February 28, 2027 | AMARASINGHE, GAYA K. | reporter.nih.gov |
| Research Program Award (R35 Clinical Trial Optional) - Dr. Robyn Klein NINDS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $3,695,974 | May 1, 2021 | October 31, 2024 | CAIN, MATTHEW D | reporter.nih.gov |
| Malaria across borders: Measuring imported infections and contributions to local transmission in Uganda and Zimbabwe | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,679,817 | June 16, 2021 | May 31, 2027 | RODRÍGUEZ-BARRAQUER, ISABEL | reporter.nih.gov |
| Neurodevelopment after postnatal Zika virus infection in infant macaques | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,679,627 | January 1, 2021 | November 30, 2026 | CHAHROUDI, ANN M | reporter.nih.gov |
| Severe Malaria And Risk to The Brain (SMART Brain) | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,674,964 | April 15, 2008 | January 31, 2029 | JOHN, CHANDY C. | reporter.nih.gov |
| Evaluation of Antibody Responses Elicited by Zika Vaccination in Flavivirus-naïve and -experienced Individuals | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,665,742 | April 13, 2021 | March 31, 2027 | KREBS, SHELLY J | reporter.nih.gov |
| PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,656,578 | March 24, 2021 | July 31, 2027 | MACLEOD, IAIN JAMES | reporter.nih.gov |
| Fosinopril analogs for the treatment of human babesiosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,646,365 | April 21, 2021 | March 31, 2027 | BEN MAMOUN, CHOUKRI | reporter.nih.gov |
| Development of a Replicon RNA-based Vaccine against Dengue and Zika | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,590,945 | June 1, 2021 | May 31, 2026 | SHRESTA, SUJAN | reporter.nih.gov |
| Optimizing the dose of tafenoquine for the radical cure of Plasmodium vivax malaria in Southeast Asia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,588,034 | September 8, 2023 | August 31, 2028 | CHU, CINDY S | reporter.nih.gov |
| Sample-to-Answer, Rapid, Multiplexed and PCR-Free Diagnostics of Arboviral Diseases in Resource Limited Settings | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,579,220 | December 23, 2020 | November 30, 2026 | YANIK, AHMET ALI | reporter.nih.gov |
| Adjuvant Development Program in the context of vaccines to protect against Y. pestis and Shigella. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $3,532,934 | September 30, 2018 | September 29, 2023 | ERNST, ROBERT | reporter.nih.gov |
| The Tick Immune Response During Microbial Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,501,084 | December 1, 2015 | May 31, 2027 | PEDRA, JOAO | reporter.nih.gov |
| Inducing durable, protective immune memory against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,488,192 | January 16, 2019 | December 31, 2023 | KAPPE, STEFAN HI | reporter.nih.gov |
| Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,469,861 | July 1, 2025 | June 30, 2028 | ROSENTHAL, PHILIP JON | reporter.nih.gov |
| Rickettsia-host interface and multiple paths to invasion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,450,818 | June 15, 2016 | May 31, 2027 | RAHMAN, MOHAMMED SAYEEDUR | reporter.nih.gov |
| A Vaccine for Lymphatic Filariasis, LFGuard™ | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,448,456 | March 1, 2019 | November 30, 2027 | CARTER, DARRICK ALBERT | reporter.nih.gov |
| Evaluating the role of P53 pathways in malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,424,681 | February 1, 2021 | January 31, 2027 | TRAN, TUAN MANH | reporter.nih.gov |
| Unraveling yellow fever 17D vaccine attenuation: The role of type I interferon and innate immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,421,854 | February 15, 2016 | July 31, 2027 | RICE, CHARLES M | reporter.nih.gov |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING STUDY TO COMPARE THE SAFETY AND EFFICACY OF 3 DOSE LEVELS OF AV-1 IN HEALTHY ADULTS CHALLENGED WITH A CONTROLLED HUMAN INFECTION S | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $3,418,636 | August 23, 2023 | July 22, 2025 | DURBIN, ANNA PALMER | reporter.nih.gov |
| Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,410,042 | February 21, 2019 | January 31, 2025 | PERLIN, DAVID S | reporter.nih.gov |
| Chemogenomic Profiling of Plasmodium Falciparum Responses and Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,402,300 | February 10, 2015 | June 30, 2027 | ADAMS, JOHN H | reporter.nih.gov |
| Uncovering the parasite and host determinants of Plasmodium vivax hypnozoite formation and development using single cell sequencing and human liver-chimeric mice | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,399,010 | February 7, 2022 | January 31, 2027 | VAUGHAN, ASHLEY M | reporter.nih.gov |
| Optimization and Modes of Action of NEU-4438, a New Anti-trypanosome Lead Drug | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,385,142 | August 19, 2016 | March 31, 2027 | MENSA-WILMOT, KOJO A. | reporter.nih.gov |
| Structure and function of the Plasmodium myosin XIV-actin glideosome. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,384,780 | May 11, 2017 | June 30, 2027 | TRYBUS, KATHLEEN M | reporter.nih.gov |
| Improving Response to Malaria Outbreaks in Amazon-Basin Countries | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,375,825 | September 1, 2025 | August 31, 2026 | PAN, WILLIAM KUANG-YAO | reporter.nih.gov |
| Drug Discovery for Chagas Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,351,347 | May 9, 2019 | December 31, 2026 | BUCKNER, FREDERICK SIMMONS | reporter.nih.gov |
| Innate Immune Activation in Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,341,812 | September 24, 2009 | February 28, 2025 | GOLENBOCK, DOUGLAS T | reporter.nih.gov |
| Elucidating the role of TSR glycosylation in Plasmodium parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,339,688 | June 1, 2020 | May 31, 2026 | SWEARINGEN, KRISTIAN EDWARD | reporter.nih.gov |
| The olfactory basis of locating nectar sugar sources in Aedes aegypti mosquitoes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,320,838 | March 5, 2021 | February 28, 2027 | RIFFELL, JEFFREY A | reporter.nih.gov |
| Second-Generation Novel Liver Stage Active Antimalarials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,320,110 | April 1, 2021 | March 31, 2027 | KELLY, JANE X | reporter.nih.gov |
| ncRNA: structure, function and inhibition | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,317,990 | April 1, 2018 | May 31, 2028 | VARANI, GABRIELE | reporter.nih.gov |
| Microbial Determinants of Excessive Inflammation and Severe Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,315,179 | September 19, 2025 | August 31, 2029 | STRLE, KLEMEN | reporter.nih.gov |
| Defining the resistome in P. falciparum: evolution and mechanism | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,309,597 | November 2, 2022 | October 31, 2027 | WINZELER, ELIZABETH A | reporter.nih.gov |
| Trypanosome Transmission Biology in Tsetse | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,303,729 | December 17, 2021 | November 30, 2026 | AKSOY, SERAP | reporter.nih.gov |
| The roles of ceramide and its derivatives in A. phagocytophilum pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,301,707 | June 6, 2018 | May 31, 2028 | CARLYON, JASON A | reporter.nih.gov |
| Small molecule-induced degradation of dengue proteins as an antiviral strategy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,293,894 | July 23, 2020 | June 30, 2025 | YANG, PRISCILLA LI-NING | reporter.nih.gov |
| B cell Epitope Discovery and Mechanisms of Antibody Protection for Enterovirus and Bunyavirus Entry Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,291,808 | September 16, 2024 | September 15, 2026 | reporter.nih.gov | |
| A structured transcriptional switching network that coordinates antigenic variation by malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,290,341 | September 22, 2021 | August 31, 2027 | DEITSCH, KIRK W | reporter.nih.gov |
| Malaria parasite determinants of host cell tropism | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,286,067 | July 1, 2022 | June 30, 2027 | DURAISINGH, MANOJ T | reporter.nih.gov |
| Once Bitten: Acquisition of Malaria Adaptive Immunity (OBAMA - Immunity) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,285,014 | July 1, 2025 | June 30, 2028 | PRUDHOMMEOMEARA, WENDY | reporter.nih.gov |
| Treating Brain Swelling in Pediatric Cerebral Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,271,417 | December 12, 2016 | November 30, 2023 | TAYLOR, TERRIE ELLEN | reporter.nih.gov |
| Pathogenic low affinity CD8 T cells in malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,264,359 | September 17, 2021 | August 31, 2026 | LAMB, TRACEY JANE | reporter.nih.gov |
| Vaccine-mediated cross-alphavirus protection for a live attenuated FDA licensed chikungunya virus vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,248,576 | July 25, 2025 | June 30, 2029 | COFFEY, LARK L | reporter.nih.gov |
| Human Monoclonal Antibodies for Encephalitic Alphaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,248,015 | July 20, 2022 | June 30, 2027 | CROWE, JAMES E | reporter.nih.gov |
| A novel Lyme disease vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,240,479 | June 7, 2022 | May 31, 2027 | FIKRIG, EROL | reporter.nih.gov |
| Spatial Targeting and Adaptive Vector Control for Residual Transmission and Malaria Elimination in Urban African Settings | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,239,370 | June 9, 2021 | May 31, 2027 | SMITH, DAVID L. | reporter.nih.gov |
| Mechanisms and consequences of extrafollicular B cell activation during malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,235,595 | September 24, 2021 | August 31, 2027 | BUTLER, NOAH SULLIVAN | reporter.nih.gov |
| Gut Microbiota Modulation of Chikungunya Virus Infection and Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,216,725 | April 1, 2021 | March 31, 2027 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Drivers of strain-specific and strain-transcendent antimalarial immunity in childhood | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,209,021 | June 17, 2020 | May 31, 2026 | GREENHOUSE, BRYAN R | reporter.nih.gov |
| Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,201,446 | May 15, 2020 | April 30, 2026 | HU, LINDEN T | reporter.nih.gov |
| Task B08: Development and Use of a Non-Human Primate Model of SARS-CoV-2 Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $3,192,083 | September 21, 2020 | June 14, 2023 | THOMPSON, KAREN | reporter.nih.gov |
| Impact of gene-drive systems for population modification on malaria vector mosquitoes | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,173,474 | June 9, 2023 | May 31, 2026 | JAMES, ANTHONY A. | reporter.nih.gov |
| Rational development of a vaccine against tick-borne rickettsioses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,166,318 | August 1, 2022 | July 31, 2027 | FANG, RONG MEGAN | reporter.nih.gov |
| Transmission dynamics and fitness of reemerging St. Louis encephalitis virus in mosquito vectors and West Nile virus naïve and immune avian reservoirs | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,161,373 | July 22, 2025 | June 30, 2029 | COFFEY, LARK L | reporter.nih.gov |
| Mechanisms Of The Unusual Cytokinesis In Trypanosomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,158,051 | June 6, 2013 | May 31, 2027 | LI, ZIYIN | reporter.nih.gov |
| The role of γδ T cells in fetal and infant immune defense against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,151,506 | March 15, 2011 | May 31, 2027 | FEENEY, MARGARET E | reporter.nih.gov |
| Analysis of a novel Crimean-Congo hemorrhagic fever vaccine and its mechanism of protection in rodent models | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,145,040 | August 25, 2022 | July 31, 2026 | SCHNELL, MATTHIAS JOHANNES | reporter.nih.gov |
| Plasmodium Protein Kinase Focused Antimalarials Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,144,589 | July 11, 2022 | June 30, 2027 | CHAKRABARTI, DEBOPAM | reporter.nih.gov |
| Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,138,902 | March 5, 2021 | February 28, 2026 | SHRESTA, SUJAN | reporter.nih.gov |
| Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,135,970 | February 1, 2019 | January 31, 2029 | DIEHL, SEAN A. | reporter.nih.gov |
| B-Cell Epitope Discovery and Mechanisms of Antibody Protection for ZIKV, MARV, VEEV Envelope Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,133,973 | September 16, 2019 | September 15, 2024 | DORANZ, BENJAMIN | reporter.nih.gov |
| Iron independent role for yersiniabactin in Yersinia pestis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,128,137 | June 4, 2021 | May 31, 2027 | LAWRENZ, MATTHEW B | reporter.nih.gov |
| Genomic consequences of schistosome hybridization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,122,895 | September 27, 2021 | August 31, 2027 | ANDERSON, TIM J | reporter.nih.gov |
| Redefining thermal suitability for urban malaria transmission in the context of humidity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,108,969 | September 14, 2020 | August 31, 2027 | MURDOCK, COURTNEY | reporter.nih.gov |
| Mechanisms of myocarditis and progressive cardiac fibrosis in chronic Trypanosoma cruzi infection. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,103,804 | March 18, 2022 | February 28, 2027 | JONES, KATHRYN MARIE | reporter.nih.gov |
| Immunological characterization of rationally-designed vaccines against plague in mice and non-human primate models | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,082,735 | February 1, 2021 | July 31, 2026 | CHOPRA, ASHOK K | reporter.nih.gov |
| Novel Therapeutics to Target Parasite Cytochrome bc1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,077,845 | July 15, 2012 | June 30, 2027 | RISCOE, MICHAEL KEVIN | reporter.nih.gov |
| Molecular basis of antimalarial drug resistance in Plasmodium vivax | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,064,807 | March 18, 2022 | February 28, 2027 | DURAISINGH, MANOJ T | reporter.nih.gov |
| Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,050,000 | July 20, 2020 | March 31, 2027 | MCDONNELL, MARK E | reporter.nih.gov |
| Point-of-care diagnostic test for T. cruzi (Chagas) infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,050,000 | August 7, 2018 | March 31, 2027 | LEVIN, ANDREW E. | reporter.nih.gov |
| Systems biological assessment of vaccination-induced protective immunity in African children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,037,984 | February 1, 2022 | January 31, 2027 | PULENDRAN, BALI | reporter.nih.gov |
| Innate Immune Mechanisms Governing Subclinical Malaria in Children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,030,131 | September 1, 2022 | August 31, 2026 | KAZURA, JAMES WALTER | reporter.nih.gov |
| Early neural predictors and neuropathogenesis of sensorimotor neurodevelopmental deficits in macaque infants exposed to Zika virus in utero | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,025,789 | June 1, 2020 | May 31, 2026 | MOHR, EMMA L | reporter.nih.gov |
| Novel Antimalarials from Fungi | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,025,049 | May 18, 2020 | April 30, 2026 | CHAKRABARTI, DEBOPAM | reporter.nih.gov |
| A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,023,104 | June 24, 2020 | June 30, 2025 | ARNABOLDI, PAUL MICHAEL | reporter.nih.gov |
| Understanding the mechanisms of antibody-mediated transcytosis of ZIKV within the placenta | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,021,123 | June 11, 2020 | May 31, 2026 | SUTHAR, MEHUL SHAMAL | reporter.nih.gov |
| Deciphering the Role of Chemokine Receptor CCR5 in Maternal Flavivirus Infections | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,021,038 | September 2, 2025 | August 31, 2029 | LIM, JEAN KYOU | reporter.nih.gov |
| A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | July 18, 2018 | March 31, 2025 | BILLINGSLEY, PETER F. | reporter.nih.gov |
| Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | August 1, 2017 | March 31, 2026 | PANG, XIAOWU | reporter.nih.gov |
| Long Lasting Organic Semiochemical Formulation to Effectively Manage Blood Sucking Diptera. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,000,000 | July 12, 2017 | January 31, 2026 | MAFRA-NETO, AGENOR | reporter.nih.gov |
| DEVELOPMENT OF COVALENTLY BOUND HYALURONIC ACID AS AN ADJUVANT FOR MULTIVALENT LYME DISEASE VACCINE | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $2,999,999 | September 30, 2024 | September 29, 2027 | PETILLO, PETER A | reporter.nih.gov |
| Cofactor metabolism and mitochondrial function in malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,998,772 | August 18, 2023 | July 31, 2027 | PRIGGE, SEAN TAYLOR | reporter.nih.gov |
| A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,998,001 | April 21, 2020 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ Optimize Formulation of VSA Adjuvant | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $2,997,218 | July 5, 2022 | July 5, 2025 | CLEMENTS, DAVID | reporter.nih.gov |
| Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,995,034 | July 14, 2022 | June 30, 2026 | MARATHI, UPENDRA | reporter.nih.gov |
| Progressing PfSPZ vaccines for malaria to licensure and commercialization | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,994,338 | April 14, 2023 | March 31, 2027 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,993,583 | March 1, 2020 | February 28, 2027 | HARTMAN, AMY L | reporter.nih.gov |
| Intranasal Vaccine Against Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,988,409 | July 12, 2022 | June 30, 2026 | GOMES-SOLECKI, MARIA | reporter.nih.gov |
| Functional investigation of a novel and essential subcellular compartment in Plasmodium falciparum transmission stage parasites | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,972,178 | March 4, 2022 | February 28, 2027 | DVORIN, JEFFREY D | reporter.nih.gov |
| Mechanisms of SFG Rickettsia-Host Interactions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,971,223 | August 12, 2021 | July 31, 2030 | LAMASON, REBECCA L | reporter.nih.gov |
| Optimization of antimalarials targeting multiple life stages of the parasite | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,967,032 | August 4, 2021 | July 31, 2027 | CARLIER, PAUL R | reporter.nih.gov |
| Learning from the Ebola success: Can a mAb also save lives after yellow fever infection? | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,966,587 | August 6, 2021 | July 31, 2025 | WATKINS, DAVID I | reporter.nih.gov |
| Chikungunya Recombinant Subunit Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,965,282 | July 22, 2016 | September 30, 2025 | CLEMENTS, DAVID E | reporter.nih.gov |
| Advancing Fast-acting Antimalarials that Disrupt Na+ Homeostasis in Parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,964,364 | August 12, 2020 | July 31, 2026 | VAIDYA, AKHIL B | reporter.nih.gov |
| Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,963,157 | February 10, 2015 | April 30, 2026 | ROSENTHAL, PHILIP JON | reporter.nih.gov |
| Self-eliminating strategy to control gene drive | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,962,580 | June 25, 2020 | May 31, 2026 | ADELMAN, ZACH N. | reporter.nih.gov |
| Artemisinin Resistance in Africa: its emergence and evolution in Rwanda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,954,668 | August 5, 2021 | July 31, 2025 | BAILEY, JEFFREY A. | reporter.nih.gov |
| Determining the interactions between mosquito oogenesis and Plasmodium falciparum survival and transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,950,744 | June 11, 2020 | May 9, 2025 | CATTERUCCIA, FLAMINIA | reporter.nih.gov |
| A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,948,061 | January 21, 2019 | July 31, 2025 | FIKRIG, EROL | reporter.nih.gov |
| Anchimerically Activatable Anti-Zika/Dengue ProTides | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,946,770 | August 1, 2021 | July 31, 2026 | WAGNER, CARSTON R. | reporter.nih.gov |
| Mechanisms of Rickettsia invasion, intracellular survival, and actin-based motility | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,937,177 | September 1, 2014 | August 31, 2028 | WELCH, MATTHEW D | reporter.nih.gov |
| A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,935,817 | July 1, 2016 | June 30, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| A universal malaria T cell vaccine based on HLA-E presentation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,934,908 | May 20, 2022 | April 30, 2027 | WILDER, BRANDON KEITH | reporter.nih.gov |
| Biomarker-Based Test of Cure for Chagas Disease | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,934,864 | July 16, 2019 | August 31, 2027 | LEVIN, ANDREW E. | reporter.nih.gov |
| Phase II STTR development of an intranasal/oral Spirulina-based PfCSP malaria vaccine. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,925,300 | May 17, 2018 | June 30, 2025 | KHUONG, NHI | reporter.nih.gov |
| Automating mosquito microdissection for a malaria PfSPZ vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,924,306 | June 20, 2017 | April 30, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,921,561 | December 15, 2016 | August 31, 2027 | GRAHAM, BRIAN BARKLEY | reporter.nih.gov |
| Genomic and geospatial analyses of malaria parasite migration to inform elimination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,915,635 | March 1, 2020 | February 28, 2026 | HARRISON, SHANNON TAKALA | reporter.nih.gov |
| Childhood Outcome After In Utero ZIKV Exposure | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,915,429 | September 10, 2020 | June 30, 2025 | MULKEY, SARAH BETH | reporter.nih.gov |
| Leveraging PfCRT Structure to Discern Function and Predict Emergence of Drug-Resistant Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,908,665 | July 1, 2019 | November 30, 2029 | MANCIA, FILIPPO | reporter.nih.gov |
| Comprehensive characterization of ancestral populations of the vector Aedes aegypti on Indian Ocean islands | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,908,225 | July 6, 2021 | December 31, 2026 | POWELL, JEFFREY R | reporter.nih.gov |
| The synergistic contributions of EBV and malaria to the etiology of Burkitt lymphoma | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,895,508 | December 12, 2019 | January 31, 2025 | SAMAYOA REYES, GABRIELA M | reporter.nih.gov |
| PreQuine Platform. A novel point of care device for the diagnosis andmonitoring of Glucose-6-Phosphate Dehydrogenase (G6PD) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,893,164 | February 8, 2017 | August 31, 2025 | HARPER, ROBERT | reporter.nih.gov |
| Structure based design of dengue subunit vaccines for inducing protective but not disease enhancing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,892,736 | April 21, 2022 | March 31, 2027 | DESILVA, ARAVINDA M. | reporter.nih.gov |
| The roles of Lyme spirochete adhesins in hematogenous dissemination | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,886,252 | February 10, 2022 | January 31, 2027 | COBURN, JENIFER L | reporter.nih.gov |
| Malaria transmission blocking through mosquito contact with treated surfaces | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,877,675 | February 4, 2020 | January 31, 2026 | CATTERUCCIA, FLAMINIA | reporter.nih.gov |
| Structure-Function Relationships in the Spirochetal Flagellar Motor | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,865,323 | February 15, 2010 | May 31, 2027 | LIU, JUN | reporter.nih.gov |
| High accuracy automated tick classification using computer vision | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,863,916 | April 18, 2022 | September 30, 2026 | GOODWIN, AUTUMN | reporter.nih.gov |
| Dual artemisinin action combats resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,862,998 | March 18, 2021 | February 28, 2027 | SULLIVAN, DAVID JOSEPH | reporter.nih.gov |
| Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,862,279 | July 15, 2020 | June 30, 2026 | GEISBERT, THOMAS WILLIAM | reporter.nih.gov |
| Gut microbiota and human malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,860,358 | July 1, 2020 | June 30, 2026 | SCHMIDT, NATHAN | reporter.nih.gov |
| JAK-STAT Control of Zika Virus-Induced Fetal Injury | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,840,817 | July 1, 2019 | June 30, 2025 | ADAMS WALDORF, KRISTINA M. | reporter.nih.gov |
| PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,838,974 | August 1, 2022 | July 31, 2025 | MACLEOD, IAIN JAMES | reporter.nih.gov |
| Multivalent Tick-Microbe targeted Lyme disease vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,836,037 | July 20, 2020 | June 30, 2027 | PAL, UTPAL | reporter.nih.gov |
| Genetic architecture of host response to tickborne disease in Peromyscus leucopus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,831,395 | September 17, 2020 | August 31, 2025 | LONG, ANTHONY DOUGLAS | reporter.nih.gov |
| Defining targets of protective immunity to vivax malaria using human monoclonal antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,825,320 | March 24, 2020 | February 28, 2026 | KING, CHRISTOPHER L | reporter.nih.gov |
| Relapsing malaria in Africa: mechanisms for persistence amid falciparum decline | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,825,021 | July 25, 2022 | June 30, 2027 | JULIANO, JONATHAN J | reporter.nih.gov |
| A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,822,362 | July 1, 2019 | June 30, 2025 | AMANNA, IAN JAMES | reporter.nih.gov |
| Importation and transmission of malaria in Zanzibar: a case study for elimination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,816,019 | August 1, 2021 | July 31, 2025 | JULIANO, JONATHAN J | reporter.nih.gov |
| An integrated approach to understand and diagnose congenital Chagas disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,811,708 | June 1, 2025 | May 31, 2027 | BOWMAN, NATALIE MCCARTER | reporter.nih.gov |
| Mechanisms of endothelial dysfunction in cerebral malaria and barrier restorative pathways | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,808,572 | September 23, 2020 | August 31, 2025 | SMITH, JOSEPH D | reporter.nih.gov |
| Accelerating Malaria Vaccines with a Custom Preclinical Humanized Mouse Model Platform | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,803,324 | March 1, 2022 | February 28, 2027 | BATISTA, FACUNDO DAMIAN | reporter.nih.gov |
| Developing a multi-component vaccine harnessing potent antibody and cellular responses against the blood-stage of Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,802,178 | May 1, 2022 | April 30, 2027 | SRINIVASAN, PRAKASH | reporter.nih.gov |
| After the flood: Optimal strategies to prevent malaria epidemics caused by severe flooding | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,800,889 | September 1, 2025 | August 31, 2028 | BOYCE, ROSS MATHEW | reporter.nih.gov |
| Chromatin Biology of the African Trypanosome | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,795,048 | June 1, 2025 | May 31, 2027 | DEBLER, ERIK | reporter.nih.gov |
| Developing capsid-importin alpha inhibitors for the treatment of VEEV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,793,911 | September 15, 2020 | August 31, 2025 | PAIGE, MIKELL | reporter.nih.gov |
| Discovery of long-acting, chemoprotective antimalarial compounds | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,791,259 | March 25, 2020 | February 28, 2026 | WINZELER, ELIZABETH A | reporter.nih.gov |
| Evaluating the Functional Impact of Genetic Diversity on Malaria Vaccine Candidates | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,788,646 | August 1, 2025 | July 31, 2027 | BEI, AMY KRISTINE | reporter.nih.gov |
| Mapping Drug Resistance Genes in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,782,422 | September 1, 2000 | November 30, 2027 | ANDERSON, TIM J | reporter.nih.gov |
| Collective Responses to Malaria Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,779,001 | February 9, 2022 | January 31, 2027 | STUART, KENNETH D | reporter.nih.gov |
| Yersinia Outer-Membrane-Vesicle Vaccines Against Pneumonic Plague | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,776,243 | January 25, 2022 | December 31, 2026 | SUN, WEI | reporter.nih.gov |
| Polymeric matrix loaded with tick repellent or toxic compositions for incorporation into fabrics or for granular dispersal | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,775,723 | September 23, 2022 | August 31, 2025 | BANFIELD, MICHAEL GILBERT | reporter.nih.gov |
| MEDSCAN: Mobile Enabled Diagnostics for Schistosomiasis Control Analytics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,773,593 | July 9, 2021 | June 30, 2027 | SCHERR, THOMAS F | reporter.nih.gov |
| Hybrid ELISA: Simple and specific one-tier assay for Lyme disease | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,764,666 | March 6, 2019 | August 31, 2027 | LEVIN, ANDREW E. | reporter.nih.gov |
| Genetics and genomics of schistosome resistance in snails | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,761,828 | June 17, 2022 | May 31, 2027 | ZHANG, SI-MING | reporter.nih.gov |
| Molecular basis of immunity to tick-borne rickettsioses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,758,756 | September 1, 2021 | August 31, 2027 | KIM, HWAN KEUN | reporter.nih.gov |
| Host and parasite factors influencing P. vivax RBC invasion and asexual development | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,748,338 | June 1, 2025 | May 31, 2027 | SERRE, DAVID | reporter.nih.gov |
| Harnessing the Malarial Immunity Omics Landscape in Vaccinated and Unvaccinated Children for Improved Therapeutic Strategies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,743,704 | July 1, 2025 | June 30, 2029 | PERKINS, DOUGLAS JAY | reporter.nih.gov |
| Neural and molecular rules of mosquito olfactory rhythms | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,742,882 | June 1, 2021 | May 31, 2027 | VINAUGER, CLEMENT | reporter.nih.gov |
| Proline homeostasis: a novel mediator of drug tolerance in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,742,796 | April 1, 2020 | March 31, 2025 | MAZITSCHEK, RALPH | reporter.nih.gov |
| Opsins and TRP channels controlling sensation and behavior in Aedes aeygpti | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,737,710 | September 24, 2021 | August 31, 2026 | MONTELL, CRAIG | reporter.nih.gov |
| Targeting Cyclic Dinucleotide Signaling Pathways to Interrupt the Nature Cycle of Borrelia burgdorferi | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,734,150 | June 9, 2020 | May 31, 2026 | YANG, X. FRANK | reporter.nih.gov |
| New Targets for Reproductive Control of Mosquito Vectors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,733,145 | June 1, 2011 | July 31, 2027 | HARRINGTON, LAURA C | reporter.nih.gov |
| Defining conserved epitopes on polymorphic malaria antigens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,726,813 | February 19, 2021 | January 31, 2027 | BUNNIK, EVELIEN MARGARETHA | reporter.nih.gov |
| Dengue-Zika: Correlates of Cross-Protection in Non-Human Primates | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,724,960 | January 9, 2020 | December 31, 2025 | SARIOL, CARLOS A | reporter.nih.gov |
| West Nile virus control through mosquitocidal avian bloodmeals | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,710,198 | September 22, 2020 | August 31, 2026 | FOY, BRIAN DAVID | reporter.nih.gov |
| Host Metabolic Biosignatures for the Diagnosis of Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,695,774 | June 19, 2019 | May 31, 2025 | BELISLE, JOHN T | reporter.nih.gov |
| Regulatory Pathways in Borrelial Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,694,240 | August 5, 2022 | July 31, 2027 | SKARE, JON T | reporter.nih.gov |
| Metabolic basis of mosquito-endosymbiont-virus interactions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,685,944 | March 1, 2020 | February 28, 2026 | PERERA, RUSHIKA | reporter.nih.gov |
| Comprehensively Defining the Novel Alphaviral Capsid Protein / IRAK1 Interaction | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,681,840 | September 4, 2025 | August 31, 2029 | SOKOLOSKI, KEVIN JOSEPH | reporter.nih.gov |
| COVID Transmission and Morbidity in Malawi (COVID-TMM) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,666,340 | April 1, 2025 | March 31, 2027 | VALIM, CLARISSA | reporter.nih.gov |
| Molecular pathways affected by drugs that disrupt Na+ and lipid homeostasis in malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,652,142 | May 5, 2017 | December 31, 2027 | VAIDYA, AKHIL B | reporter.nih.gov |
| Lead optimization and target identification of drugs targeting hypnozoites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,647,674 | August 7, 2020 | July 31, 2025 | KYLE, DENNIS E | reporter.nih.gov |
| Host factors and viral determinants mediating flavivirus NS1 tissue-specific endothelial dysfunction and vascular leak | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,639,200 | April 18, 2022 | March 31, 2027 | HARRIS, EVA | reporter.nih.gov |
| The molecular and cellular basis of short-range host cue sensing in mosquito vectors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,636,373 | September 21, 2020 | August 31, 2025 | GARRITY, PAUL | reporter.nih.gov |
| Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies in Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,627,211 | August 1, 2008 | August 31, 2025 | ROSENTHAL, PHILIP JON | reporter.nih.gov |
| Understanding alpha-gal red meat allergy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,615,501 | September 24, 2018 | January 31, 2029 | COMMINS, SCOTT PALMER | reporter.nih.gov |
| DEVELOPMENT OF A BROAD-SPECTRUM THERAPEUTIC | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $2,609,829 | September 23, 2016 | September 30, 2022 | RAMSTEDT, URBAN | reporter.nih.gov |
| Baseline host and environmental factors that impact pre-erythrocytic malaria vaccine (hypo)responsiveness in endemic regions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,600,040 | March 8, 2022 | February 28, 2027 | YAZDANBAKHSH, MARIA | reporter.nih.gov |
| Population genomics and new tools for the endgame of onchocerciasis elimination in Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,588,507 | December 1, 2019 | November 30, 2025 | MITREVA, MAKEDONKA | reporter.nih.gov |
| Global Research Endeavors to Advance Treatment of Neurological Disorders in Africa (GREAT Neurology) | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,561,391 | May 1, 2021 | April 30, 2029 | BIRBECK, GRETCHEN L. | reporter.nih.gov |
| Tick Saliva and Pathogen Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,544,342 | May 9, 2018 | June 30, 2029 | PEDRA, JOAO | reporter.nih.gov |
| Defining the Role of PfCRT and PfMDR1 as Pleiotropic Mediators of Plasmodium falciparum Multidrug Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,538,591 | August 1, 2001 | January 31, 2028 | FIDOCK, DAVID A | reporter.nih.gov |
| Assessing desiccation tolerance's impact on Aedes aegypti midgut infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,536,503 | September 8, 2025 | August 31, 2029 | DICKSON, LAURA B | reporter.nih.gov |
| Vaccines for Prevention of RG3 and RG4 Emerging Tickborne Viral Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,523,497 | August 20, 2021 | July 31, 2026 | VERARDI, PAULO H | reporter.nih.gov |
| Novel Multiple-Stage Active Antimalarials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,520,964 | June 14, 2019 | August 31, 2030 | KANCHARLA, PAPIREDDY | reporter.nih.gov |
| Implicating a previously unknown Dectin1-RIPK2-CARD9 signaling in providing resistance against Leishmania major infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,516,676 | March 24, 2021 | February 28, 2027 | GURUNG, PRAJWAL | reporter.nih.gov |
| Enhancing dengue virus genomic surveillance to uncover circulating genetic diversity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,514,500 | September 21, 2022 | August 31, 2027 | GRUBAUGH, NATHAN DALE | reporter.nih.gov |
| Membrane Protein Effectors of Pathogen Interactions With Host | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $2,510,135 | June 1, 2016 | May 31, 2026 | MARASSI, FRANCESCA M | reporter.nih.gov |
| Opsins as a new class of evolutionarily conserved taste receptors | NIH | National Institute on Deafness and Other Communication Disorders | 2021 to 2025 | $2,503,868 | June 1, 2017 | May 31, 2027 | MONTELL, CRAIG | reporter.nih.gov |
| Optimization of Antischistosomal Chemotypes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,501,475 | February 1, 2015 | March 31, 2026 | VENNERSTROM, JONATHAN L | reporter.nih.gov |
| A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $2,501,040 | September 30, 2023 | September 29, 2028 | TSUJI, MORIYA | reporter.nih.gov |
| Development of vaccines targeting a tick-borne phlebovirus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,499,856 | July 10, 2020 | June 30, 2025 | BATES, PAUL | reporter.nih.gov |
| A clear view of encephalitis: a single cell approach to determine the basis of flaviviral pathogenesis in the central nervous system | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,486,737 | January 21, 2022 | December 31, 2026 | RICE, CHARLES M | reporter.nih.gov |
| Zika virus nonstructural protein 5 inhibition of interferon signaling | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,477,738 | August 21, 2023 | July 31, 2027 | EVANS, MATTHEW J | reporter.nih.gov |
| Translation of evolution-guided insights for new models of human infectious disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,475,525 | May 6, 2021 | April 30, 2026 | MITCHELL, PATRICK S | reporter.nih.gov |
| Malaria associated pathogenesis of chronic kidney disease (MAP-CKD) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,470,944 | June 1, 2025 | May 31, 2027 | CONROY, ANDREA L. | reporter.nih.gov |
| Development of a pre-erythrocytic P. vivax vaccine to prevent clinical relapse | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,467,626 | January 1, 2019 | December 31, 2023 | SATHER, D. NOAH | reporter.nih.gov |
| Drug Target Discovery, Validation, and Prioritization for Schistosomiasis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,457,864 | December 20, 2022 | November 30, 2027 | COLLINS, JAMES J | reporter.nih.gov |
| Impairment of anti-Plasmodium T cell memory by type I Interferon Signaling | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,456,734 | June 1, 2023 | May 31, 2028 | MINKAH, NANA KWAKU | reporter.nih.gov |
| Genital Immune, Mucosal, and Viral Effects of Female Genital Schistosomiasis in Tanzania | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,453,764 | March 25, 2022 | February 28, 2027 | DOWNS, JENNIFER ALZOS | reporter.nih.gov |
| Innovative therapeutic strategies to support elimination of river blindness | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,445,389 | September 11, 2023 | August 31, 2027 | MITREVA, MAKEDONKA | reporter.nih.gov |
| Molecular Aspects of Tsetse and Trypanosome Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,438,925 | January 11, 2019 | December 31, 2025 | AKSOY, SERAP | reporter.nih.gov |
| Sex ratio distortion in Aedes aegypti | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,436,620 | September 16, 2020 | August 31, 2025 | TU, ZHIJIAN JAKE | reporter.nih.gov |
| Long-term neurocognitive outcomes of HIV-exposed uninfected children | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2024 | $2,434,267 | July 17, 2022 | June 30, 2026 | LAUFER, MIRIAM K. | reporter.nih.gov |
| Identification of novel anthelmintics through a target-based screen of a parasite ion channel | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,419,635 | March 5, 2021 | February 28, 2026 | MARCHANT, JONATHAN S | reporter.nih.gov |
| Immunity to Liver-stage malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,414,340 | January 12, 2022 | January 14, 2025 | HARTY, JOHN T | reporter.nih.gov |
| Epidemiology and determinants of emerging artemisinin-resistant malaria in Ethiopia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,413,258 | June 9, 2023 | May 31, 2028 | PARR, JONATHAN BOYD | reporter.nih.gov |
| Olfactory modulation of color vision and behavior in mosquitoes | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,412,809 | February 16, 2023 | January 31, 2028 | RIFFELL, JEFFREY A | reporter.nih.gov |
| Toward novel therapies against Lyme disease through the inhibition of lysinoalaine cross-linking in the bacterial flagella. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,405,876 | August 16, 2021 | July 31, 2025 | CRANE, BRIAN R | reporter.nih.gov |
| Defining the role of the RNA modification N6-methyladenosine during Flaviviridae virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,403,276 | June 1, 2016 | January 31, 2027 | HORNER, STACY MICHELLE | reporter.nih.gov |
| UV to blue neuronal phototransduction mechanisms | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,402,747 | April 1, 2018 | March 31, 2028 | HOLMES, TODD C | reporter.nih.gov |
| Elucidating the Role of Endocytosis Via the Cytostome in the Life Cycle of Trypanosoma cruzi | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,399,085 | June 1, 2021 | May 31, 2027 | ETHERIDGE, RONALD DREW | reporter.nih.gov |
| An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,389,767 | June 12, 2020 | May 31, 2025 | KLIMSTRA, WILLIAM B | reporter.nih.gov |
| Innate Immune Regulation of Zika Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,388,284 | March 1, 2019 | February 28, 2025 | GALE, MICHAEL | reporter.nih.gov |
| Cyclic di-AMP-dependent signaling in tickborne relapsing fever Borrelia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,380,916 | August 8, 2022 | July 31, 2027 | BLEVINS, JON SCOTT | reporter.nih.gov |
| Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,374,490 | July 10, 2014 | June 30, 2025 | MOORMANN, ANN M | reporter.nih.gov |
| Liver resident memory for malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,368,344 | November 23, 2018 | October 31, 2024 | MURPHY, SEAN C | reporter.nih.gov |
| Maturation of human humoral immunity through repeat malaria challenges | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,367,571 | May 24, 2023 | April 30, 2028 | WILLIAMSON, KIM C | reporter.nih.gov |
| Conserved mechanisms of ciliary signaling and cell-cell fusion | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $2,363,676 | September 20, 2022 | June 30, 2027 | SNELL, WILLIAM J | reporter.nih.gov |
| Rigorous Assessment of P. vivax Relapses and Primaquine Efficacy for Radical Cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,362,550 | July 17, 2020 | June 30, 2026 | SERRE, DAVID | reporter.nih.gov |
| Parasite and host cell factors involved in the formation and persistence of Plasmodium vivax hypnozoites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,358,624 | February 9, 2023 | January 31, 2028 | KAPPE, STEFAN HI | reporter.nih.gov |
| From Drosophila Immunity to Anti-Inflammatories | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,351,847 | February 15, 2004 | November 30, 2027 | SILVERMAN, NEAL | reporter.nih.gov |
| Role of human innate immune mutations in loss of tolerance to Borrelia burgdorferi | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,344,769 | September 8, 2020 | August 31, 2025 | HU, LINDEN T | reporter.nih.gov |
| Virulence Mechanisms of Multifunctional Borrelial Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,337,463 | June 15, 2020 | August 16, 2024 | GARCIA, BRANDON LEE | reporter.nih.gov |
| Hijacking Plasmodium ubiquitin-proteasome system to defeat drug resistance | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,334,364 | July 1, 2023 | June 30, 2028 | LIN, GANG | reporter.nih.gov |
| Durable Schistosome induced metabolic alterations to the myeloid lineage | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,333,788 | March 5, 2021 | February 28, 2026 | FAIRFAX, KEKE CELESTE | reporter.nih.gov |
| The Biology of Stem Cells in the Human Parasite Schistosoma Mansoni | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,328,971 | February 1, 2016 | January 31, 2026 | COLLINS, JAMES J | reporter.nih.gov |
| Reassortment of Bunyavirus in ticks and animal models | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,326,633 | August 19, 2022 | July 31, 2027 | JUNG, JAE U | reporter.nih.gov |
| Flavivirus immunity in endemic and non-endemic human cohorts | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,322,225 | February 16, 2021 | January 31, 2027 | MESSER, WILLIAM | reporter.nih.gov |
| Developing methionyl tRNA synthetase inhibitors as therapeutics for Chagas disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,320,008 | April 1, 2020 | March 31, 2026 | FAN, ERKANG | reporter.nih.gov |
| Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,318,306 | March 14, 2023 | February 29, 2028 | AMARASINGHE, GAYA K. | reporter.nih.gov |
| Investigations of Lyme spirochete transmission as a complex network of microbial and ecological interactions | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $2,315,379 | September 16, 2022 | July 31, 2027 | COURET, JANNELLE | reporter.nih.gov |
| Elucidating the functions of red blood cell factors in malaria parasite invasion | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,314,537 | July 1, 2023 | June 30, 2028 | EGAN, ELIZABETH S. | reporter.nih.gov |
| Anti-flavivirus B cell response analysis to aid vaccine design | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,304,231 | February 6, 2023 | January 31, 2028 | LI, YUXING | reporter.nih.gov |
| Resolving the properties of schistosome TRPMPZQ, the target of the anthelmintic drug praziquantel | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,302,312 | April 1, 2020 | March 31, 2030 | MARCHANT, JONATHAN S | reporter.nih.gov |
| Development of Inhibitors Targeting Flavivirus Methyltransferase | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,302,146 | April 7, 2023 | March 31, 2028 | LI, HONGMIN | reporter.nih.gov |
| A Self-Adjuvanting Virus Like Particle Vaccine Platform for Emerging Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,297,827 | June 8, 2023 | May 31, 2028 | DEFILIPPIS, VICTOR ROBERT | reporter.nih.gov |
| Surveillance to track and characterize antimalarial resistance trends in Ugandan Plasmodium falciparum parasites (STARTUP) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,293,828 | December 20, 2022 | November 30, 2025 | CONRAD, MELISSA D | reporter.nih.gov |
| Orientia tsutsugamushi Ank-host interactions in scrub typhus pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,292,269 | February 15, 2022 | January 31, 2027 | CARLYON, JASON A | reporter.nih.gov |
| Mechanisms of Neuronal Infection by Prototype Emerging Bunyaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,287,685 | August 7, 2023 | July 31, 2027 | HARTMAN, AMY L | reporter.nih.gov |
| TMEM41B: a pan-flavivirus and pan-coronavirus host factor with antiviral potential | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,286,496 | September 19, 2022 | July 31, 2027 | RICE, CHARLES M | reporter.nih.gov |
| Emerging Flea-Borne Rickettsial Diseases: vector competence and transmission biology | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,286,335 | December 1, 2015 | July 31, 2027 | MACALUSO, KEVIN R. | reporter.nih.gov |
| Identity, function and control of Francisella effectors encoded outside its pathogenicity island | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,279,849 | July 1, 2019 | June 30, 2025 | MOUGOUS, JOSEPH DAVID | reporter.nih.gov |
| Development of next-generation gene drive technologies for Anopheles population engineering | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,276,593 | June 1, 2021 | May 31, 2026 | BIER, ETHAN | reporter.nih.gov |
| A modular platform for infectious disease surveillance at point-of-need. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,274,286 | August 7, 2020 | August 31, 2025 | FISHER, JAY KENNETH | reporter.nih.gov |
| Regulation of RIG-I signaling and viral immune evasion by ufmylation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,272,375 | June 1, 2021 | May 31, 2026 | HORNER, STACY MICHELLE | reporter.nih.gov |
| Dengue virus mRNA lipid nanoparticle vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,268,440 | August 12, 2021 | July 31, 2025 | RICHNER, JUSTIN | reporter.nih.gov |
| Aedes antiviral RNAi pathway | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,267,812 | November 20, 2018 | October 31, 2025 | DIMOPOULOS, GEORGE | reporter.nih.gov |
| Development of a Virus-Like Particle Vaccine for Powassan Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,265,539 | June 1, 2020 | May 31, 2026 | HIRSCH, ALEC J | reporter.nih.gov |
| Defining P. falciparum resistance to artemisinin-based combination therapies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,262,645 | August 1, 2014 | February 28, 2027 | FIDOCK, DAVID A | reporter.nih.gov |
| SFTSV nonstructural protein NSs-mediated immunopathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,260,994 | July 1, 2018 | June 30, 2024 | JUNG, JAE U | reporter.nih.gov |
| Long Term Immunity Following Yellow Fever Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,259,248 | February 5, 2020 | January 31, 2026 | MESSER, WILLIAM | reporter.nih.gov |
| Develop a candidate subunit vaccine for Powassan Virus and West Nile virus adjuvanted with Alhydroxiquim-II | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $2,258,969 | September 30, 2018 | September 29, 2023 | DAVID, SUNIL | reporter.nih.gov |
| Tickborne SFTS Virus Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,258,000 | August 3, 2020 | July 31, 2026 | JUNG, JAE U | reporter.nih.gov |
| Sex determination and the sex-determining locus in aedine mosquitoes | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,254,128 | July 14, 2023 | June 30, 2028 | TU, ZHIJIAN JAKE | reporter.nih.gov |
| Disentangling the human vector relationship to disrupt dengue and chikungunya virus outbreaks in Kenya | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,253,756 | July 5, 2013 | April 30, 2025 | LABEAUD, ANGELLE DESIREE | reporter.nih.gov |
| US-UK Collab: Modelling reassortment at the cellular, clinical, and phylogenetic level in emerging Bunyaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,245,998 | July 1, 2021 | June 30, 2027 | MOLINA-PARIS, CARMEN | reporter.nih.gov |
| Mechanisms of Antibody-Dependent Enhancement of Dengue Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,244,008 | September 24, 2018 | August 31, 2028 | BOURNAZOS, STYLIANOS | reporter.nih.gov |
| Developing New Statistical Methods for Vector-Borne Disease Surveillance to Improve Accuracy while Reducing Cost | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,240,192 | September 19, 2023 | July 31, 2028 | SELF, STELLA COKER WATSON | reporter.nih.gov |
| CD8 T cell-dependent pathways leading to immunopathology in cutaneous leishmaniasis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,230,533 | February 12, 2020 | January 31, 2025 | SCOTT, PHILLIP | reporter.nih.gov |
| CD8 T cell mediated disruption of Blood Brain Barrier Tight Junctions | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,226,916 | July 1, 2017 | February 28, 2030 | JOHNSON, AARON J | reporter.nih.gov |
| MEP pathway resistance in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,223,785 | December 1, 2012 | March 31, 2028 | ODOM JOHN, AUDREY RAGAN | reporter.nih.gov |
| Elucidating Chemical Signaling Mechanisms that Regulate Multicellularity and the Transmission of Infectious Disease | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,219,184 | August 1, 2020 | July 31, 2030 | GERDT, JOSEPH P. | reporter.nih.gov |
| ANTIBODY-BASED PROTECTION AGAINST FLAVIVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,212,878 | September 15, 2007 | January 31, 2029 | DIAMOND, MICHAEL S | reporter.nih.gov |
| OspC and its role in defining host range and dissemination properties | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,211,024 | August 1, 2022 | July 31, 2026 | MARCONI, RICHARD T | reporter.nih.gov |
| SpoVG and PlzA Regulation of Lyme Disease Spirochete Infection Processes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,207,935 | April 1, 2020 | March 31, 2026 | STEVENSON, BRIAN | reporter.nih.gov |
| Etiology of Persistent Microalbuminuria in Nigeria | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,202,068 | July 1, 2021 | May 31, 2026 | WESTER, C. WILLIAM | reporter.nih.gov |
| Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,198,656 | September 21, 2020 | August 31, 2025 | HORWITZ, MARCUS AARON | reporter.nih.gov |
| Quasispecies dynamics in arbovirus persistence emergence and fitness | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,197,799 | May 15, 2007 | January 31, 2027 | EBEL, GREGORY DAVID | reporter.nih.gov |
| Rocky Mountain Spotted Fever Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,192,703 | September 1, 2021 | August 31, 2027 | GANTA, ROMAN R. | reporter.nih.gov |
| Probing Functional States and Inhibition of Flaviviral Proteases Using Nanopore Tweezers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,190,088 | June 10, 2021 | May 31, 2027 | CHEN, MIN | reporter.nih.gov |
| Biogenic amines, malaria and manipulation of mosquito physiology and behavior. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,184,819 | August 8, 2022 | July 31, 2027 | LUCKHART, SHIRLEY | reporter.nih.gov |
| Borrelia gene products critical for natural infection cycle | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,181,619 | July 1, 2009 | July 31, 2025 | PAL, UTPAL | reporter.nih.gov |
| Identification of the initial cells infected by West Nile virus ex vivo and in vivo | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,178,310 | September 21, 2022 | July 31, 2027 | LIM, JEAN KYOU | reporter.nih.gov |
| Impact of inflammatory lipids on Yersinia pestis infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,171,406 | July 14, 2023 | June 30, 2027 | LAWRENZ, MATTHEW B | reporter.nih.gov |
| Characterizing sexual development of the human parasite Schistosoma mansoni | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,152,107 | July 1, 2020 | June 30, 2025 | COLLINS, JAMES J | reporter.nih.gov |
| The paradox of flavivirus antigenic non-reciprocity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,146,248 | July 24, 2024 | May 31, 2029 | FRIEDRICH, THOMAS C. | reporter.nih.gov |
| Non-inferiority trial of a therapeutic vaccine against Chagas disease in naturally-infected rhesus macaques | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,145,891 | February 16, 2023 | January 31, 2028 | DUMONTEIL, ERIC | reporter.nih.gov |
| Investigating astrocytic RIPK3 as a driver of protective neuroinflammation during viral encephalitis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,142,099 | February 15, 2021 | January 31, 2027 | DANIELS, BRIAN | reporter.nih.gov |
| Role of IgE in human disease and immunity to ticks | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,139,543 | March 20, 2024 | January 31, 2026 | SMITH, SCOTT ALAN | reporter.nih.gov |
| Predictors of cardiomyopathy progression in a Chagas disease cohort in Bolivia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,136,387 | February 15, 2014 | June 30, 2024 | GILMAN, ROBERT H | reporter.nih.gov |
| Mechanisms of alphavirus infectivity and adaptation - Resubmission - 1 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,136,232 | February 1, 2022 | January 31, 2027 | STAPLEFORD, KENNETH | reporter.nih.gov |
| Mechanisms of viral RNA maturation by co-opting cellular exonucleases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,134,101 | June 1, 2023 | May 31, 2027 | KIEFT, JEFFREY S | reporter.nih.gov |
| Uganda Schistosomiasis Multidisciplinary Research Centre (U-SMRC) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,130,877 | May 1, 2025 | April 30, 2027 | ELLIOTT, ALISON | reporter.nih.gov |
| Biogenesis of the Trypanosoma brucei subpellicular microtubule array | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,127,931 | September 17, 2021 | August 31, 2026 | DE GRAFFENRIED, CHRISTOPHER LUIS | reporter.nih.gov |
| Defining the mechanism of coma in cerebral malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,123,692 | July 8, 2022 | June 30, 2027 | DAILY, JOHANNA PATRICIA | reporter.nih.gov |
| Multi-Omics Characterization of Plasmodium Vivax Hypnozoites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,118,231 | December 22, 2022 | November 30, 2027 | SERRE, DAVID | reporter.nih.gov |
| Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,114,325 | April 11, 2019 | March 31, 2025 | MANETSCH, ROMAN | reporter.nih.gov |
| Genome-wide sieve analysis and immunological validation to identify targets of protective efficacy in field trials of a whole-organism malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,110,841 | January 15, 2019 | December 31, 2024 | CARNEIRO DA SILVA, JOANA | reporter.nih.gov |
| The role of natural killer cells and antibodies in protection from malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,108,688 | March 25, 2020 | February 28, 2026 | HART, GEOFFREY T | reporter.nih.gov |
| Molecular genetics of gustatory detection | NIH | National Institute on Deafness and Other Communication Disorders | 2021 to 2025 | $2,107,835 | July 1, 2006 | June 30, 2026 | MONTELL, CRAIG | reporter.nih.gov |
| Essential early events in the flavivirus lifecycle | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,093,750 | March 9, 2021 | February 28, 2027 | UCHIL, PRADEEP D | reporter.nih.gov |
| Control of VSG pre-mRNA processing in infectious Trypanosoma brucei | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,093,750 | September 23, 2021 | August 31, 2026 | TSCHUDI, CHRISTIAN | reporter.nih.gov |
| Intra-tick and intra-host infection dynamics of a tick-borne bunyavirus | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,092,645 | July 1, 2022 | June 30, 2027 | HERMANCE, MEGHAN ELIZABETH | reporter.nih.gov |
| PlzA, cyclic-di-GMP and the enzootic cycle for Lyme disease | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,090,540 | November 18, 2022 | October 31, 2027 | MARCONI, RICHARD T | reporter.nih.gov |
| Repurposing human kinase inhibitor chemotypes for Neglected Tropical Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,089,227 | December 4, 2014 | March 31, 2026 | FERRINS, LORI | reporter.nih.gov |
| Mechanism and Inhibition of Thogotovirus Entry | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,085,008 | November 22, 2022 | October 31, 2027 | BOON, ADRIANUS CM | reporter.nih.gov |
| THE IDENTIFICATION AND VALIDATION OF EPITOPES CONSERVED IN VIRAL PATHOGEN FAMILIES WITH PANDEMIC POTENTIAL | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,080,465 | September 30, 2025 | September 29, 2026 | FABRITZKY, BRANDON | reporter.nih.gov |
| Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infection | NIH | National Eye Institute | 2021 to 2024 | $2,079,783 | January 1, 2021 | December 31, 2025 | ARUMUGASWAMI, VAITHILINGARAJA | reporter.nih.gov |
| Innate immune signaling in placental antiviral defenses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,078,112 | July 17, 2019 | June 30, 2025 | COYNE, CAROLYN B | reporter.nih.gov |
| New tools for tick-borne pathogen surveillance | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,075,697 | December 8, 2022 | November 30, 2027 | OLIVER, JONATHAN D | reporter.nih.gov |
| Field trial and modeling of transmission blocking vaccine to prevent Lyme disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,072,628 | June 19, 2019 | May 31, 2025 | BROWN, GRANT D | reporter.nih.gov |
| Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,067,031 | April 1, 2003 | June 30, 2029 | GILBERT, PETER B. | reporter.nih.gov |
| Epitope-Based CSP Vaccines Optimized to Achieve Long-Term Sterile Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,065,107 | August 23, 2023 | July 31, 2027 | MILICH, DAVID R. | reporter.nih.gov |
| Esophageal gland-mediated immune evasion by the human parasite Schistosoma mansoni | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,064,827 | August 24, 2023 | July 31, 2028 | LEE, JAYHUN | reporter.nih.gov |
| The roles of Anaplasma phagocytophilum surface proteins in infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,062,336 | July 15, 2007 | June 30, 2027 | CARLYON, JASON A | reporter.nih.gov |
| Peptide regulation of mosquito blood feeding and mating | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,059,337 | August 1, 2020 | August 31, 2030 | DUVALL, LAURA | reporter.nih.gov |
| Task A71: Comprehensive In Vivo Screening of Viral Pathogens of Pandemic Potential | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,055,396 | August 3, 2022 | August 2, 2025 | BOWEN, RICHARD ARNOLD | reporter.nih.gov |
| Defining correlates of protection from dengue illness in a long-term cohort study of multigenerational house-holds in Thailand | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,054,463 | July 1, 2025 | June 30, 2028 | ANDERSON, KATHRYN B | reporter.nih.gov |
| Plasmodium falciparum gametocytogenesis in vitro and in vivo | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,054,301 | January 8, 2020 | December 31, 2025 | WILLIAMSON, KIM C | reporter.nih.gov |
| Trade-offs between Arbovirus Transmission and Clearance in Native and Novel Hosts | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,054,277 | February 24, 2020 | January 31, 2025 | HANLEY, KATHRYN ALYCE | reporter.nih.gov |
| The evolutionary genetics and genomics of Wolbachia effects on host physiology | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,054,249 | August 4, 2017 | July 31, 2027 | COOPER, BRANDON S. | reporter.nih.gov |
| Tick-Pathogen Interactions: Exploring the Intersection between Stress Responses and Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,049,089 | July 11, 2022 | June 30, 2027 | SHAW, DANA KATHLEEN | reporter.nih.gov |
| The role of stem-cell mediated midgut repair in the dynamics of mosquito infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,045,645 | June 5, 2020 | May 31, 2026 | BUCHON, NICOLAS | reporter.nih.gov |
| Systemic Neurotropic virus infection effects on GI Dysmotility | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,043,482 | July 1, 2020 | April 30, 2025 | STAPPENBECK, THADDEUS S | reporter.nih.gov |
| Schistosomiasis at the edge of elimination: characterizing sources of new infections in residual transmission hotspots | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,041,847 | November 23, 2018 | October 31, 2025 | CARLTON, ELIZABETH | reporter.nih.gov |
| The essential role of cyclin-dependent kinase CRK9 in trypanosome pre-mRNA processing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,037,700 | March 2, 2021 | February 28, 2027 | GUNZL, ARTHUR | reporter.nih.gov |
| Vanderbilt University Medical Center (VUMC) CoFAR Clinical Research Center | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,036,652 | March 14, 2024 | February 28, 2031 | BACHARIER, LEONARD B | reporter.nih.gov |
| Function and Trafficking of Flagellar Membrane Proteins in Leishmania mexicana | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,026,198 | May 22, 2023 | April 30, 2028 | LANDFEAR, SCOTT M | reporter.nih.gov |
| Function of hemolymph plasma proteins in insect immune responses | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,022,182 | May 1, 2021 | February 28, 2027 | KANOST, MICHAEL R | reporter.nih.gov |
| The Function of Antimalarial Drug Resistance Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,016,655 | June 15, 2003 | October 31, 2026 | ROEPE, PAUL D. | reporter.nih.gov |
| Scramblases for protein glycosylation | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $2,015,483 | April 1, 2022 | March 31, 2027 | MENON, ANANT K | reporter.nih.gov |
| Germline Transformation of Ticks | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,013,002 | May 11, 2023 | April 30, 2028 | GULIA-NUSS, MONIKA | reporter.nih.gov |
| The evolution of copy number variations in the AT-rich Plasmodium genome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,000,646 | April 1, 2021 | March 31, 2027 | GULER, JENNIFER LYNN | reporter.nih.gov |
| FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $2,000,000 | July 17, 2020 | April 30, 2025 | WYCOFF, KEITH | reporter.nih.gov |
| Commercialization Readiness Pilot (CRP) program support for: Ultra-sensitive, direct-from-blood, molecular detection of Borrelia infections. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,000,000 | April 2, 2024 | March 31, 2027 | SINGER, ALON | reporter.nih.gov |
| Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,999,755 | December 8, 2023 | November 30, 2026 | LOCHER, CHRISTOPHER | reporter.nih.gov |
| Rapid Point-of-Care RNA Diagnostic for Dengue Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,999,598 | March 15, 2019 | July 31, 2025 | CHO, HYUNDAE | reporter.nih.gov |
| REPEAT-CONTAINING RNA BINDING PROTEINS OF TRYPANOSOMES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,998,600 | January 5, 2015 | January 31, 2026 | AFASIZHEVA, INNA | reporter.nih.gov |
| Role of microglia in neural infection | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,997,135 | January 15, 2022 | December 31, 2026 | WU, PING | reporter.nih.gov |
| Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,995,482 | April 21, 2016 | July 31, 2027 | CHAKRAVARTY, SUMANA | reporter.nih.gov |
| Malarial retinopathy screening system for improved diagnosis of cerebral malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,992,098 | May 6, 2021 | April 30, 2024 | JOSHI, VINAYAK S | reporter.nih.gov |
| Targeted Prevention of Human Ehrlichiosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,991,816 | August 17, 2021 | July 31, 2027 | RIKIHISA, YASUKO | reporter.nih.gov |
| Development of Next-gen Chagas DetectTM Plus Rapid test for sensitive and specific diagnosis of Chagas disease | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,988,974 | May 8, 2024 | April 30, 2027 | RAYCHAUDHURI, SYAMAL X | reporter.nih.gov |
| The role of pattern recognition and autophagy in innate anti-bunyaviral immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,986,831 | September 23, 2019 | August 31, 2025 | CHERRY, SARA | reporter.nih.gov |
| Role of Zika virus (ZIKV) infection in glaucoma pathobiology | NIH | National Eye Institute | 2021 to 2025 | $1,980,186 | September 1, 2021 | August 31, 2027 | SINGH, PAWAN KUMAR | reporter.nih.gov |
| PfSPZ Vaccine for Malaria: Towards a Successful Biologics License Application and Commercialization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,973,577 | February 15, 2004 | June 30, 2023 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Development of an automated IVD for the ultra-sensitive, direct, molecular detection of Borrelia for early Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,972,995 | June 15, 2020 | May 31, 2024 | SINGER, ALON | reporter.nih.gov |
| Reproductive Responses to the Zika Virus Epidemic in Brazil | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $1,969,272 | September 15, 2018 | June 30, 2023 | MARTELETO, LETICIA J | reporter.nih.gov |
| Structural Studies of Togaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,968,857 | February 20, 2012 | January 31, 2025 | KUHN, RICHARD J. | reporter.nih.gov |
| A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,967,096 | July 1, 2020 | June 30, 2027 | AMANNA, IAN JAMES | reporter.nih.gov |
| An immune system for the city: a new paradigm for control of urban disease vectors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,967,064 | July 1, 2019 | June 30, 2025 | LEVY, MICHAEL Z | reporter.nih.gov |
| Brain pathology and function in a chronic mouse model of ZIKV transmission | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,965,040 | April 1, 2019 | March 31, 2024 | TERSKIKH, ALEXEY V | reporter.nih.gov |
| Advancing evolutionary genetics through deep learning | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,962,893 | July 1, 2020 | April 30, 2030 | SCHRIDER, DANIEL R | reporter.nih.gov |
| Mechanisms of visual transduction and light-driven behaviors in Aedes aegypti | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,960,699 | January 1, 1995 | January 31, 2027 | MONTELL, CRAIG | reporter.nih.gov |
| Model-based inference and forecasting of co-circulating pathogen dynamics | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,956,250 | September 24, 2021 | June 30, 2027 | PERKINS, ALEX | reporter.nih.gov |
| Ultrasensitive, High-Specificity Rapid Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,954,629 | May 1, 2022 | June 30, 2027 | BIAMONTE, MARCO ANTONIO | reporter.nih.gov |
| Mechanistic Analysis of Zika Virus Induced Placental Damage During Pregnancy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $1,951,673 | June 1, 2019 | May 31, 2025 | STREBLOW, DANIEL N | reporter.nih.gov |
| Identifying functional antibody responses that protect against malaria in children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,938,902 | August 1, 2025 | July 31, 2027 | SEYDEL, KARL BOYNTON | reporter.nih.gov |
| Employing viruses to unravel the functional significance of the m5C epitranscriptome | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,938,825 | February 7, 2023 | January 31, 2028 | RICE, CHARLES M | reporter.nih.gov |
| Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,938,759 | April 21, 2016 | May 31, 2024 | CHAKRAVARTY, SUMANA | reporter.nih.gov |
| Perturbations of host cell signaling by a complex hepatotropic pathogen | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,938,593 | April 1, 2013 | January 31, 2028 | KAUSHANSKY, ALEXIS | reporter.nih.gov |
| A point of care vertical flow assay for the direct detection of Babesia microti and the serodiagnosis of Lyme disease. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,933,868 | July 1, 2024 | February 28, 2027 | DATTWYLER, RAYMOND JAMES | reporter.nih.gov |
| Exploring the coevolutionary potential of chikungunya virus and its Aedes mosquito vectors | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,932,881 | May 19, 2023 | April 30, 2028 | MCGRAW, ELIZABETH ANN | reporter.nih.gov |
| Mechanistic Insights into flavivirus NS5-mediated STAT2 Suppression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,932,088 | March 15, 2021 | February 28, 2026 | HAI, RONG | reporter.nih.gov |
| Cryopreservation of Anopheles Embryos | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,928,928 | August 1, 2010 | January 31, 2024 | BILLINGSLEY, PETER F. | reporter.nih.gov |
| Comprehensive Definition of the Critical Role(s) of the Alphaviral Noncapped Genomic RNAs to Infection and Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,927,696 | May 21, 2020 | April 30, 2026 | SOKOLOSKI, KEVIN JOSEPH | reporter.nih.gov |
| Modeling the influence of temperature on the evolution of vector-virus interactions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,926,486 | February 3, 2022 | January 31, 2027 | CIOTA, ALEXANDER TIMOTHY | reporter.nih.gov |
| Dissecting the role of EBV and P. falciparum in endemic Burkitt lymphoma pathogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,923,862 | August 14, 2019 | January 31, 2025 | LUFTIG, MICAH A. | reporter.nih.gov |
| Impairment of B cell Responses by Pathogenic Chikungunya Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,921,199 | January 25, 2019 | December 31, 2024 | MORRISON, THOMAS E | reporter.nih.gov |
| Identifying Wolbachia effectors that facilitate host infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,918,425 | May 10, 2019 | March 31, 2029 | NEWTON, IRENE | reporter.nih.gov |
| Defining the immunogenic landscape of early mosquito-stage P. falciparum to accelerate malaria transmission-blocking vaccine discovery | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,917,896 | July 5, 2024 | May 31, 2029 | SWEARINGEN, KRISTIAN EDWARD | reporter.nih.gov |
| Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,915,091 | April 3, 2021 | March 31, 2026 | MORRIS, JAMES CULVIN | reporter.nih.gov |
| In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,912,715 | February 15, 2010 | May 31, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Trypanosoma cruzi dormancy and its implications for therapeutic treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,908,036 | March 10, 2020 | February 28, 2026 | TARLETON, RICK L | reporter.nih.gov |
| Molecular Mechanisms Underlying Insect Odorant Receptor Function and Modulation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,907,239 | December 15, 2013 | November 30, 2025 | RUTA, VANESSA | reporter.nih.gov |
| Understanding Unique Aspects of Motility and Chemotaxis in Borrelia burgdorferi | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,906,728 | September 19, 2008 | January 31, 2027 | LI, CHUNHAO CHRIS | reporter.nih.gov |
| Antibody-based Protection against Flavivirses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,903,581 | September 15, 2007 | March 13, 2024 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Functional analysis of host and viral determinants for ZAP inhibition | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,901,640 | April 1, 2021 | March 31, 2027 | LI, MELODY | reporter.nih.gov |
| Molecular mechanisms of schizogony in malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,900,856 | June 1, 2019 | May 31, 2025 | DVORIN, JEFFREY D | reporter.nih.gov |
| Dissection of molecular events driving alphavirus entry and assembly | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,900,539 | August 15, 1995 | November 30, 2024 | KIELIAN, MARGARET | reporter.nih.gov |
| Natural Product Inspired Novel Antimalarials with Radical Cure Potential | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,900,470 | April 4, 2023 | March 31, 2028 | KANCHARLA, PAPIREDDY | reporter.nih.gov |
| Uncovering and harnessing connected metabolic pathways essential to virus infection. | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,891,981 | September 1, 2020 | May 31, 2030 | MOUNCE, BRYAN C | reporter.nih.gov |
| Role of Translesional Polymerases in Genome Diversification of the Malaria Parasite | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,889,240 | June 10, 2019 | May 31, 2025 | KIRKMAN, LAURA | reporter.nih.gov |
| Type-I Interferons drive cell-autonomous immunity to malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,887,500 | June 21, 2022 | May 31, 2027 | KURUP, SAM | reporter.nih.gov |
| Real-time tracking of virus evolution for vaccine strain selection and epidemiological investigation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,886,759 | August 23, 2016 | May 31, 2026 | BEDFORD, TREVOR BC | reporter.nih.gov |
| Discovery of early immunologic biomarkers for risk of PTLDS through machine learning-assisted broad temporal profiling of humoral immune response | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,885,162 | July 7, 2023 | June 30, 2028 | WOODBURY, NEAL WALTER | reporter.nih.gov |
| Slo-1K channels, TRP-2 channels, emodepside and diethylcarbamazine in Filaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,876,476 | September 16, 2020 | August 31, 2025 | MARTIN, RICHARD JOHN | reporter.nih.gov |
| Safety and Immunogenicity of novel, live-attenuated V4020 vaccine for Venezuelan Equine Encephalitis (VEE) in healthy adults | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,876,310 | March 1, 2022 | February 28, 2026 | PUSHKO, PETER M. | reporter.nih.gov |
| Efficacy of novel reservoir-host targeted bait formulations against a tick-borne pathogen | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,875,000 | September 1, 2021 | August 31, 2026 | SESHU, JANAKIRAM | reporter.nih.gov |
| Unlocking serology’s secrets: harnessing novel immune biomarkers to predict Lyme disease progression and recovery | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,872,987 | July 1, 2023 | June 30, 2028 | TAL, MICHAL CASPI | reporter.nih.gov |
| Next Generation Infectious Disease Diagnostics: Microfluidic-Free Gigapixel PCR with Self-Assembled Partitioning | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,871,100 | June 15, 2023 | May 31, 2028 | ABATE, ADAM R. | reporter.nih.gov |
| Regulation of cell cycle transitions by cyclin-dependent kinase in trypanosomes | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,869,624 | May 13, 2016 | April 30, 2027 | LI, ZIYIN | reporter.nih.gov |
| Virulence regulation by BadR in the Lyme disease spirochete | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,868,750 | March 24, 2021 | February 28, 2027 | OUYANG, ZHIMING | reporter.nih.gov |
| Determinants of Post-Treatment Phenotypes in Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,868,460 | July 1, 2023 | June 30, 2028 | AUCOTT, JOHN | reporter.nih.gov |
| Statistical innovation to integrate sequences and phenotypes for scalable phylodynamic inference | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,862,316 | April 9, 2021 | March 31, 2026 | SUCHARD, MARC A. | reporter.nih.gov |
| Innate immune recognition and response to Rift Valley fever virus | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,861,528 | August 25, 2022 | July 31, 2027 | MCELROY, ANITA K | reporter.nih.gov |
| How to starve a parasite: Manipulating CoA biosynthesis to control Plasmodium development in the mosquito | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,855,815 | April 14, 2023 | March 31, 2027 | RIEHLE, MICHAEL ALLEN | reporter.nih.gov |
| Biomarkers to Identify Individuals at RIsk for Progression of S. Japonicum Associated Hepatic Fibrosis with Point of Care Test Development | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,852,531 | June 1, 2022 | March 31, 2027 | FRIEDMAN, JENNIFER F | reporter.nih.gov |
| Clearance of Blood-Borne Arboviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,851,575 | January 21, 2020 | December 31, 2025 | MORRISON, THOMAS E | reporter.nih.gov |
| Transfusion-related immunomodulation influences infectious disease outcomes | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,851,251 | September 1, 2020 | June 30, 2025 | SIMMONS, GRAHAM | reporter.nih.gov |
| Genetic mechanisms of snail/schistosome compatibility | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,848,750 | January 10, 2019 | May 31, 2028 | BLOUIN, MICHAEL SCOTT | reporter.nih.gov |
| Precision guided SIT for the control of vector-borne disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,847,066 | January 23, 2020 | December 31, 2024 | AKBARI, OMAR SULTAN | reporter.nih.gov |
| Primaquine metabolism and treatment of P. vivax in Madagascar | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,843,113 | January 1, 2020 | September 19, 2023 | ZIMMERMAN, PETER A. | reporter.nih.gov |
| Virus-like Particle based malaria vaccines targeting vulnerable epitopes in the circumsporozoite protein | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,841,511 | November 9, 2022 | October 31, 2027 | CHACKERIAN, BRYCE C | reporter.nih.gov |
| Host and parasite determinants of Leishmania Viannia persistence in naturally infected human populations | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,833,337 | December 28, 2022 | November 30, 2027 | EL-SAYED, NAJIB M | reporter.nih.gov |
| Auto-antibodies as predictive markers for Post treatment Lyme Disease Syndrome | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,830,220 | July 5, 2023 | June 30, 2028 | HU, LINDEN T | reporter.nih.gov |
| SUPPORTING WHO ONCHOCERCIASIS ELIMINATION PROGRAMS: PROGRESSING A HIGHLY SENSITIVE AND ULTRA-SPECIFIC RAPID DIAGNOSTIC TEST TO COMMERCIALIZATION READINESS | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,829,744 | March 16, 2023 | February 28, 2026 | BIAMONTE, MARCO ANTONIO | reporter.nih.gov |
| Genome-based diagnostics for mapping, monitoring and management of insecticide resistance in major African malaria vectors | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,808,286 | February 15, 2016 | May 31, 2027 | DONNELLY, MARTIN JAMES | reporter.nih.gov |
| Targeting a New Therapy for Trypanosomatids | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,805,632 | June 12, 2019 | May 31, 2025 | WETZEL, DAWN MARIE | reporter.nih.gov |
| Mosquito hydration status as a mechanism that alters pre-feeding host interactions and post-feeding physiology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,800,822 | June 12, 2020 | May 31, 2026 | BENOIT, JOSH B. | reporter.nih.gov |
| Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in Africa | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,796,782 | December 23, 2010 | June 30, 2029 | PARIKH, SUNIL | reporter.nih.gov |
| Partial maturation in mosquito-borne flaviviruses: developing new approaches to characterize the role of lattice heterogeneity in fusion, infectivity, and antibody neutralization | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,790,590 | January 20, 2022 | December 31, 2026 | METSKAS, LAUREN ANN | reporter.nih.gov |
| Antiviral and immunomodulatory effects of interferon lambda in the skin | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,784,166 | March 13, 2023 | February 29, 2028 | LAZEAR, HELEN | reporter.nih.gov |
| POLYAMINE AND TRYPANOTHIONE METABOLISM IN TRYPANOSOMA BRUCEI | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,783,125 | December 1, 1994 | June 30, 2026 | PHILLIPS, MARGARET A. | reporter.nih.gov |
| Extent, dynamics and mechanisms of Plasmodium vivax immune evasion caused by PvDBP gene amplification | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,777,806 | July 1, 2025 | June 30, 2028 | POPOVICI, JEAN | reporter.nih.gov |
| Snail-Related Studies of Transmission & Control of Schistosomiasis in Kenya | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,777,676 | May 15, 2012 | April 30, 2027 | LOKER, ERIC SAMUEL | reporter.nih.gov |
| Impacts of phenology on disease transmission dynamics | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,776,375 | August 1, 2023 | July 31, 2028 | BRISSON, DUSTIN | reporter.nih.gov |
| Immunological characterization of the P. vivax DBP | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,773,948 | August 1, 2006 | March 31, 2026 | ADAMS, JOHN H | reporter.nih.gov |
| A novel strategy for vaccine-induced protection against maternal-to-fetal transmission of Zika virus | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,768,228 | June 7, 2024 | April 30, 2029 | SHRESTA, SUJAN | reporter.nih.gov |
| Innate Immunity to West Nile Virus | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,763,090 | July 1, 2024 | May 31, 2029 | OBERST, ANDREW ATWELL | reporter.nih.gov |
| Antibody-mediated immunity to Borrelia burgdorferi | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,759,416 | March 8, 2021 | February 28, 2027 | BAUMGARTH, NICOLE | reporter.nih.gov |
| Essential PK/PD relationships of antimalarial drugs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,753,200 | February 1, 2012 | August 31, 2025 | SHAPIRO, THERESA A | reporter.nih.gov |
| The role of ascorbate in myelopoiesis and infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,753,030 | April 1, 2021 | July 31, 2026 | AGATHOCLEOUS, MICHALIS | reporter.nih.gov |
| Caspase-8 as a focal hub in effector-triggered immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,752,183 | May 10, 2019 | April 30, 2025 | LIEN, EGIL | reporter.nih.gov |
| Cellular and humoral immunity in Lyme arthritis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,748,421 | January 8, 2019 | June 30, 2024 | STEERE, ALLEN C | reporter.nih.gov |
| DISCOVERY AND PRECLINICAL DEVELOPMENT OF EFFICACIOUS P. vivax PRE-ERYTHROCYTIC STAGE MALARIA VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,745,498 | November 20, 2020 | October 31, 2023 | HERRERA VALENCIA, SOCRATES | reporter.nih.gov |
| Comprehensive characterization of the genetic factors and the host immune response associated to protection from clinical Plasmodium vivax malaria | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,744,699 | March 16, 2023 | February 29, 2028 | POPOVICI, JEAN | reporter.nih.gov |
| Once bitten: A longitudinal, observational study of successful malaria parasite transmission events between humans and mosquitos | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,739,571 | July 16, 2019 | June 30, 2024 | PRUDHOMMEOMEARA, WENDY | reporter.nih.gov |
| Origin of the innate immunity suppression caused by nairovirus' protease activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,738,279 | September 16, 2020 | August 31, 2025 | PEGAN, SCOTT DUSAN | reporter.nih.gov |
| A multidisciplinary approach to study ecotypes driving transmission and pathogenesis of Visceral Leishmaniasis (VL) and Post kala-azar dermal leishmaniasis (PKDL) in Eastern Africa | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,736,288 | April 1, 2025 | March 31, 2027 | SATOSKAR, ABHAY R | reporter.nih.gov |
| Peptide-vaccine development against Lyme disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,724,972 | May 15, 2020 | April 30, 2026 | BARBIER, MARIETTE | reporter.nih.gov |
| Mitochondrial Functions in Malaria Parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,717,892 | July 1, 1989 | October 31, 2028 | VAIDYA, AKHIL B | reporter.nih.gov |
| Structure-based Vaccine Design for CCHFV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,714,028 | June 25, 2020 | November 30, 2025 | MCLELLAN, JASON SCOTT | reporter.nih.gov |
| ER-shaping proteins of Plasmodium | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,698,924 | June 1, 2021 | May 31, 2027 | BHANOT, PURNIMA | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of Washington | Seattle, WA | 40 | $71.5 million | 0 | $0 |
| Washington University | Saint Louis, MO | 48 | $71.5 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 45 | $66.1 million | 0 | $0 |
| Emory University | Atlanta, GA | 22 | $53.6 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 49 | $53.6 million | 0 | $0 |
| Yale University | New Haven, CT | 41 | $52.3 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 42 | $45 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 47 | $41.9 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 20 | $41 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 39 | $40.1 million | 0 | $0 |
| Sanaria, Inc. | Rockville, MD | 20 | $39.5 million | 0 | $0 |
| Duke University | Durham, NC | 31 | $39 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 26 | $38.8 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 13 | $37 million | 0 | $0 |
| Stanford University | Stanford, CA | 23 | $32.8 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 31 | $31.6 million | 0 | $0 |
| University of Vermont & ST Agric College | Burlington, VT | 4 | $29.8 million | 0 | $0 |
| Colorado State University | Fort Collins, CO | 22 | $26.4 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 18 | $26 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 23 | $24.6 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 27 | $24.3 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 16 | $23.4 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 16 | $23.3 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 24 | $23.1 million | 0 | $0 |
| Rockefeller University | New York, NY | 11 | $23.1 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 16 | $22.2 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 4 | $22 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 16 | $21.8 million | 0 | $0 |
| Virginia Polytechnic Institute and State University | Blacksburg, VA | 31 | $21.5 million | 0 | $0 |
| University of California at Davis | Davis, CA | 15 | $21.5 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 19 | $21.4 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 13 | $21.3 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 25 | $21.2 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 11 | $20.5 million | 0 | $0 |
| University of South Florida | Tampa, FL | 20 | $19.6 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 17 | $18.3 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 18 | $18.2 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 16 | $17.7 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 13 | $17 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 11 | $16.3 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 5 | $15.5 million | 0 | $0 |
| Pennsylvania State Univ University Park | University Park, PA | 19 | $15.4 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 15 | $15.1 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 17 | $15 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 2 | $14.8 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 11 | $14.6 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 7 | $14.3 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 14 | $14.2 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 16 | $13.7 million | 0 | $0 |
| Cornell University | Ithaca, NY | 13 | $13.7 million | 0 | $0 |
| Brown University | Providence, RI | 15 | $13.6 million | 0 | $0 |
| Washington State University | Pullman, WA | 15 | $13.5 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 12 | $13.5 million | 0 | $0 |
| University of California-Riverside | Riverside, CA | 15 | $13.3 million | 0 | $0 |
| Ohio State University | Columbus, OH | 12 | $12.8 million | 0 | $0 |
| Drexel University | Philadelphia, PA | 10 | $12.8 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 10 | $12.7 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 10 | $12.7 million | 0 | $0 |
| Utah State University | Logan, UT | 2 | $12.1 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 10 | $11.9 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 9 | $11.8 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 11 | $11.7 million | 0 | $0 |
| University of Louisville | Louisville, KY | 9 | $11.7 million | 0 | $0 |
| Clemson University | Clemson, SC | 3 | $11.4 million | 0 | $0 |
| Abviro, LLC | Bethesda, MD | 2 | $11.4 million | 0 | $0 |
| Health Research Incorporated/New York State Department of Health | Menands, NY | 2 | $10.8 million | 0 | $0 |
| Kephera Diagnostics, LLC | Framingham, MA | 6 | $10.6 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 12 | $10.5 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 5 | $10.5 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 10 | $10.4 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 13 | $10.2 million | 0 | $0 |
| George Mason University | Fairfax, VA | 2 | $10.2 million | 0 | $0 |
| University of California-Santa Barbara | Santa Barbara, CA | 6 | $10 million | 0 | $0 |
| Children's Research Institute | Washington, DC | 5 | $9.2 million | 0 | $0 |
| Henry M. Jackson FDN for the Adv Mil/med | Bethesda, MD | 6 | $9.2 million | 0 | $0 |
| University of Chicago | Chicago, IL | 4 | $9.2 million | 0 | $0 |
| L2 Diagnostics, LLC | New Haven, CT | 13 | $9.1 million | 0 | $0 |
| Brandeis University | Waltham, MA | 5 | $9.1 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 6 | $8.8 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 8 | $8.6 million | 0 | $0 |
| Texas Biomedical Research Institute | San Antonio, TX | 6 | $8.4 million | 0 | $0 |
| Iowa State University | Ames, IA | 16 | $8.2 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 5 | $8.2 million | 0 | $0 |
| University of Montana | Missoula, MT | 7 | $8.1 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 5 | $8.1 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 6 | $8 million | 0 | $0 |
| Biomedical Research Institute | Rockville, MD | 1 | $7.9 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 9 | $7.9 million | 0 | $0 |
| Texas A&m Agrilife Research | College Station, TX | 12 | $7.8 million | 0 | $0 |
| The University of Central Florida Board of Trustees | Orlando, FL | 4 | $7.8 million | 0 | $0 |
| Portland State University | Portland, OR | 3 | $7.7 million | 0 | $0 |
| University of Florida | Gainesville, FL | 9 | $7.7 million | 0 | $0 |
| George Washington University | Washington, DC | 5 | $7.3 million | 0 | $0 |
| Hawaii Biotech, Inc. | Honolulu, HI | 4 | $7.2 million | 0 | $0 |
| Kansas State University | Manhattan, KS | 7 | $7.2 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 2 | $7.2 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 7 | $7 million | 0 | $0 |
| University of South Carolina at Columbia | Columbia, SC | 3 | $6.6 million | 0 | $0 |
| Aldatu Biosciences, Inc. | Watertown, MA | 2 | $6.5 million | 0 | $0 |
| Integral Molecular | Philadelphia, PA | 2 | $6.4 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 859 | $452,768,585 | 0 | $0 |
| 2024 | 914 | $476,069,053 | 0 | $0 |
| 2023 | 904 | $457,637,023 | 0 | $0 |
| 2022 | 969 | $511,263,816 | 0 | $0 |
| 2021 | 1,022 | $513,132,051 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 13 awards here | |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 4 awards here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) | PA-24-182 | NIH | May 8, 2027 | Not listed | Notice number printed on 3 awards here | |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 1,645 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 1,645 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 1,645 awards here |
Updated November 4, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-04). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.